The changing landscape of mammalian cell culture manufacturing capacity
Recent technological advances in manufacturing processes, improvements in expression levels, widespread acceptance of single-use bioreactors, an increase in biosimilar development throughout the world, and consolidation in the pharmaceutical and biopharmaceutical industries have resulted in significant changes in the supply and demand of mammalian cell culture manufacturing capacity. Currently, the vast majority of global mammalian cell culture manufacturing capacity is controlled by just a few biopharmaceutical companies. As a result, access to capacity and utilization of manufacturing capacity varies considerably throughout the industry. This presentation will discuss current trends that will influence the growth, availability, and utilization of cell culture capacity in the coming years and provide insights into the future of global biopharmaceutical manufacturing.